Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Journal of Clinical Oncology, 08/02/2012
Clinical Article
Johnson NA et al. – Assessment of MYC and BCL2 expression by immunohistochemistry (IHC) represents a robust, rapid, and inexpensive approach to risk–stratify patients with Diffuse large B–cell lymphoma (DLBCL) at diagnosis.



